Patents Assigned to Temple University
-
Publication number: 20160262384Abstract: The present disclosure provides an antimicrobial composition including a polycationic amphiphile compound, and the method of making and the method of using such a compound or composition. The compound having the formula (I) or (II) R1, R2, R3, R4, R5, R6, R10, or R11 is H or a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —NR?2, —N—C(0)R?, —N—C(0)CR??CR?, —SH, —SR?, -0-C(0)R?, —C(0)R?, —CF3, —OCF3, halogen, benzyl, o-vinylbenzyl, m-vinylbenzyl, p-vinylbenzyl, phenyl, allyl, and substituted allyl. R7, R8 or R9 is a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —NR?2, —SH, —SR?, -0-C(0)R?, —C(0)R?, —CF3, and —OCF3. R? is H or a C1-4 alkyl. X or Y is a halogen, m and n are integers in the range from 1 to 25.Type: ApplicationFiled: November 5, 2014Publication date: September 15, 2016Applicants: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, VILLANOVA UNIVERSITYInventors: William WUEST, Kevin Patrick MINBIOLE
-
Publication number: 20160250300Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.Type: ApplicationFiled: May 6, 2016Publication date: September 1, 2016Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Kamel KHALILI, Wenhui HU
-
Publication number: 20160242413Abstract: The present disclosure provides an antimicrobial composition including a polycationic amphiphile compound, and the method of making and the method of using such a compound or composition. The compound having the formula R1, R2, R3, R4, R5, R6, R10, or R11 is H or a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —N—C(O)R?, —N—C(O)CR??CR?, —SH, —SR?, —O—C(O)R?, —C(O)R?, —CF3, —OCF3, halogen, benzyl, o-vinylbenzyl, m-vinylbenzyl, p-vinylbenzyl, phenyl, allyl, and substituted allyl. R7, R8 or R9 is a C1-12 alkyl unsubstituted or optionally substituted with a functional group such as —OH, —OR?, —NH2, —NHR?, —SH, —SR?, —O—C(O)R?, —C(O)R?, —CF3, and —OCF3. R? is H or a C1-4 alkyl. X or Y is a halogen. m and n are integers in the range from 1 to 25.Type: ApplicationFiled: May 5, 2016Publication date: August 25, 2016Applicants: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, VILLANOVA UNIVERSITYInventors: William WUEST, Kevin Patrick MINBIOLE
-
Patent number: 9402853Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.Type: GrantFiled: March 13, 2013Date of Patent: August 2, 2016Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATIONInventors: Arthur G Schwartz, John R Williams
-
Publication number: 20160214303Abstract: The present invention includes a robotic system for the enhanced automation, manipulation, and control of electroprocessing in two or three dimensions. In one embodiment, the system includes a sealed chamber devoid of any electrical or conductive components which would interfere with the electrical field and eventual material fabrication, while still allowing for two-dimensional and three-dimensional robot motion. In certain embodiments, the system of the invention produces materials or scaffolds with complex shapes, including materials with ridges, valleys, curves, and the like, which are difficult or impossible to construct using traditional systems.Type: ApplicationFiled: August 22, 2014Publication date: July 28, 2016Applicant: Temple University-Of the Commonwealth System of Higher EducationInventors: Jonathan A. Gerstenhaber, Peter I. Lelkes
-
Patent number: 9374941Abstract: Provided is a method for seed priming comprising the steps of treating seed with a seed priming composition comprising sieved compost, hydrogel and water in a ratio of sieved compost:hydrogel:water of from about 5:1:4.75 to about 9:1:11 by weight in an amount sufficient to result in priming of the seed. In some embodiments, the seed is treated with from about 2 to about 39 grams of the seed priming composition per gram of seed. In preferred embodiments, the seed composition and the seed priming composition are free of soil or sand. In further preferred embodiments, the seed is blended with the seed priming composition at a temperature of about 5° C. to about 25° C.Type: GrantFiled: September 12, 2012Date of Patent: June 28, 2016Assignee: TEMPLE UNIVERSITY -OF THE COMMON-Inventor: Michael W. Olszewski
-
Publication number: 20160146785Abstract: Compositions include nucleic acid sequences encoding the C-terminal fragment of fragment (Seg3) of Nuclear factor-erythroid 2 related factor 2 (Nrf2). These compositions provide a target for identification of novel therapeutics having the ability to modulate the translation of Nrf2. Methods of treating subjects are also provided.Type: ApplicationFiled: October 9, 2013Publication date: May 26, 2016Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Oscar M. PEREZ-LEAL, Salim MERALI, Carlos A. BARRERO
-
Publication number: 20160115124Abstract: Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.Type: ApplicationFiled: November 5, 2015Publication date: April 28, 2016Applicants: UNIVERSITY OF ROCHESTER, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, TEMPLE UNIVERSITY -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Paul M. Dunman, Patrick D. Olson, Wayne Childers
-
Patent number: 9316184Abstract: An apparatus (100) for reducing the size of fuel particles injected into a combustion chamber is disclosed. The apparatus includes fuel line (110), a first metallic mesh (114) disposed within the fuel line (110), and a second metallic mesh (112) disposed within the fuel line (110), upstream of the first metallic mesh (114). An electrical supply (130) is electrically coupled to the first metallic mesh (114) and the second metallic mesh (112). Operation of the electrical supply (130) generates an electrical field between the first metallic mesh (114) and the second metallic mesh (112). A fuel injector (120) is disposed at an end of the fuel line (110), downstream from the first metallic mesh (114). Methods of reducing the size of fuel particles, improving gas mileage in a vehicle, increasing power output from a combustion engine, and improving emissions for a combustion engine are also provided.Type: GrantFiled: October 30, 2007Date of Patent: April 19, 2016Assignee: Temple University of the Commonwealth System of Higher EducationInventors: Rongjia Tao, Ke Huang, Deepika Khilnaney-Chhabria, Edward Kaczanowicz
-
Publication number: 20160017301Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.Type: ApplicationFiled: August 29, 2014Publication date: January 21, 2016Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Kamel Khalili, Wenhui Hu
-
Publication number: 20160018403Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from “redoxin proteins” selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.Type: ApplicationFiled: July 15, 2015Publication date: January 21, 2016Applicant: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. CHANG, George P. Tuszynski
-
Publication number: 20160016941Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.Type: ApplicationFiled: March 11, 2014Publication date: January 21, 2016Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
-
Patent number: 9163088Abstract: The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3?untranslated region (3?UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy.Type: GrantFiled: October 26, 2007Date of Patent: October 20, 2015Assignee: Temple UniversityInventor: Xiao-Feng Yang
-
Publication number: 20150283118Abstract: Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease.Type: ApplicationFiled: June 19, 2015Publication date: October 8, 2015Applicants: UNIVERSITY OF ROCHESTER, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, TEMPLE UNIVERSITY -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Paul M. Dunman, Patrick D. Olson, Wayne Childers
-
Patent number: 9140704Abstract: Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers.Type: GrantFiled: July 13, 2010Date of Patent: September 22, 2015Assignee: Temple University of The Commonwealth System of Higher EducationInventors: Frank N. Chang, Phu T. Duong, George P. Tuszynski
-
Patent number: 9044036Abstract: The present invention relates to a method and an apparatus for producing a chocolate product. The method includes delivering liquid chocolate having a viscosity through a pipe along a delivery path to a production station for producing the chocolate product. The liquid chocolate includes solid particles suspended within the liquid chocolate. The method changes the viscosity of the liquid chocolate by applying an electric field to the liquid chocolate in a direction along the delivery path of a strength and duration determined to aggregate the suspended solid particles into streamlined shapes extending along the direction of the delivery path.Type: GrantFiled: January 31, 2013Date of Patent: June 2, 2015Assignee: Temple University-of the Commonwealth System of Higher EducationInventors: Rongjia Tao, Hong Tang
-
Patent number: 9040583Abstract: Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation.Type: GrantFiled: July 14, 2010Date of Patent: May 26, 2015Assignees: Temple University-Of the Commonwealth System of Higher Education, Duke University, Research Triangle InstituteInventors: Mary E. Abood, Pingwei Zhao, Lawrence S. Barak, Herbert H. Seltzman
-
Publication number: 20150140127Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.Type: ApplicationFiled: June 25, 2013Publication date: May 21, 2015Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
-
Patent number: 9001325Abstract: In apparatus and methods of Raman spectroscopy in air, a target region is excited by a laser pump pulse exceeding the critical power for self-focusing in air and having a duration after self-focusing of 15 fs or less. A laser probe pulse having a duration in the range of 200 fs to 100 ps and an energy of at least 20 ?J is directed at the excited target region. Stimulated Raman scattering from the interaction between the excited target region and the laser probe pulse is detected. The target region can be outside the spectrometer, with ambient air in between used for the self-focusing.Type: GrantFiled: February 3, 2012Date of Patent: April 7, 2015Assignee: Temple University —Of The Commonwealth System of Higher EducationInventors: Robert J. Levis, Johanan H. Odhner
-
Patent number: 8980269Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.Type: GrantFiled: March 13, 2013Date of Patent: March 17, 2015Assignee: Temple University of the Commonwealth System of Higher EducationInventors: Frank N. Chang, George P. Tuszynski
